Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment
Rhea-AI Summary
Silo Pharma (Nasdaq: SILO) reported that the Canadian Intellectual Property Office issued a Notice of Allowance for a patent application covering its lead asset SPC-15, an intranasal 5-HT4 receptor agonist targeting PTSD and other stress-induced psychiatric disorders.
According to Silo Pharma, the Canadian application, licensed exclusively from Columbia University, covers methods to prevent or delay stress-induced fear and depressive-like behavior and enhance stress resilience. Corresponding IP has been granted or is progressing in multiple international markets, including a recently granted European patent. The company intends to pursue the FDA’s streamlined 505(b)(2) pathway for SPC-15 and highlights a broader pipeline in CNS and pain, alongside its managed AI agent subsidiary, QwikAgents.
Positive
- Canadian Notice of Allowance issued for SPC-15 patent application covering PTSD-related methods
- SPC-15 Canadian patent rights held under an exclusive license from Columbia University
- Corresponding SPC-15 IP granted or advancing in multiple international markets, including Europe
- Company plans to use FDA’s 505(b)(2) pathway for SPC-15 development
Negative
- None.
Market Reaction – SILO
Following this news, SILO has declined 10.16%, reflecting a significant negative market reaction. Argus tracked a peak move of +14.4% during the session. Our momentum scanner has triggered 33 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $2.76. Trading volume is exceptionally heavy at 67.5x the average, suggesting significant selling pressure.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 10 | European patent grant | Positive | +1.2% | European patent grant expanded protection for SPC-15’s preventative PTSD treatment approach. |
| Aug 06 | AI platform partnership | Positive | +1.3% | QwikAgents engaged Caylent to build an AWS-native enterprise AI platform. |
| Jul 21 | Pipeline progress update | Positive | +0.2% | Silo outlined QwikAgents commercialization and SPC-15 development milestones. |
| Jul 14 | AI program enrollment | Positive | -2.8% | QwikAgents joined AMD’s AI Developer Program with access to cloud credits and tools. |
| Jul 10 | Private placement | Negative | -26.3% | Silo announced equity and warrant financing for working capital and corporate purposes. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Patent and partnership announcements were followed by positive reactions, while the private placement and one AI-program announcement diverged negatively.
Key Terms
notice of allowance regulatory
5-ht4 receptor agonist medical
505(b)(2) regulatory pathway regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Follows recent European patent grant and coverage in multiple international markets as Silo continues to strengthen licensed IP portfolio for lead therapeutic program
SARASOTA, FLA., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems with a wholly owned managed AI agent platform subsidiary, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15, an intranasal 5-HT4 receptor agonist targeting post-traumatic stress disorder (PTSD) and other stress-induced psychiatric disorders. The Company has an exclusive license for the Canadian patent application as part of its broader license agreement with Columbia University to further develop, manufacture, and commercialize SPC-15 globally.
The allowed patent application, titled “Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress,” covers methods of preventing or delaying stress-induced fear and depressive-like behavior and methods for inducing and/or enhancing stress resilience by administering selected serotonin 4 (5-HT4) receptor agonists prior to a stressor. Corresponding intellectual property has been granted or is advancing in multiple international markets, including a recently granted European patent covering the same core invention.
“The Canadian patent allowance adds to our momentum in securing broad international protection for SPC-15,” said Eric Weisblum, Chief Executive Officer of Silo Pharma. “With corresponding claims receiving protection across multiple markets, we continue to strengthen the global IP position of SPC-15 and our broader therapeutic portfolio.”
Silo intends to utilize the FDA’s streamlined 505(b)(2) regulatory pathway for SPC-15, which could shorten clinical timelines and reduce development costs
About Silo Pharma, Inc.
Silo Pharma is a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for post-traumatic stress disorder (PTSD), SP-26 for fibromyalgia and chronic pain, and a preclinical asset targeting Alzheimer’s disease. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com
QwikAgents, Silo Pharma's wholly owned artificial intelligence subsidiary, is a managed AI agent platform that delivers dedicated autonomous agents for research, content generation, scheduling, and workflow automation each running in a persistent environment with proprietary smart-routing across multiple AI models. The subsidiary reflects Silo's strategy to expand into high-growth technology markets while continuing to advance its core biopharmaceutical pipeline. qwikagents.com
Forward Looking Statements
This news release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including statements about changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
(800) 705-0120
investors@silopharma.com
